Anti-PCSK9 (Alirocumab), Human IgG1 Antibody

Anti-PCSK9 (Alirocumab), Human IgG1 Antibodyis available at Gentaur for Next week Delivery.

Description: The research-grade biosimilar antibody is a fully human IgG1 monoclonal antibody that binds to and inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), an enzyme that has "gain-of-function" mutations in autosomal dominant hypercholesterolemia. PCSK9 is secreted by the liver and binds to the LDL receptors in serum and marks them for lysosomal degradation. As a result, the LDL receptors are unable to recycle to the plasma membrane, thus reducing their binding to LDL-C and subsequent clearance of LDL-C from plasma. Therefore, by binding to free PCSK9, the biosimilar allows more LDL-C reuptake by the liver and facilitates a higher rate of clearance of LDL-C. The original drug received approval from the FDA as a second-line of treatment for heterozygous familial hypercholesterolemia in adults, whose LDL-C was not controlled by the combination of diet and statin treatment.

Immunogen Sequence:Human PCSK9

Target Alternative Name:REGN727, SAR-236553, FH3; PC9; FHCL3; NARC1; LDLCQ1; NARC-1; HCHOLA3

Species Reactivities:Human

Tag Line:The biosimilar is a human monoclonal antibody that binds to free PCSK9 and promotes degradation of this enzyme, thereby facilitating more uptake of LDL-C by the liver and a higher rate of clearance from circulation. The original drug received FDA approval to treat adults with heterozygous familial hypercholesterolemia

Formulation:In PBS, pH 7.5

Purification: Protein A purified

Application:/

Positive Control:/

Application And Usages:/

Handling:The antibody solution should be gently mixed before use.